Autologous hematopoietic stem cell transplant

PROCEDURE4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), City of Hope Medical Center, Gary A Levy, O. Ont. MD. FRCP AGAF, Sichuan University

Conditions

Complication of Transplanted Organ, NosLymphoma, Large B-Cell, DiffuseLymphoma, T-CellRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRelapsing-Remitting Multiple Sclerosis

Phase 2

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

CompletedNCT00288626

National Institute of Allergy and Infectious Diseases (NIAID)Relapsing-Remitting Multiple Sclerosis

Start: 2006-07-31End: 2015-11-30Updated: 2017-09-19

Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance

CompletedNCT02549586

Gary A Levy, O. Ont. MD. FRCP AGAFComplication of Transplanted Organ, Nos

Start: 2015-12-31End: 2020-04-30Updated: 2021-04-28

Phase 3

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

TerminatedNCT02366663

City of Hope Medical CenterRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

Start: 2015-01-31End: 2016-10-31Updated: 2018-03-12

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Sichuan UniversityLymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell

Start: 2022-07-01End: 2025-12-30Target: 306Updated: 2022-07-25

Related Papers

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

2017-02-01112 citations